#1Health Partners P P3 People. Passion. Purpose. Health Partners P3 P3 Investor Presentation Health Partner MAPP.C A Proner May 2021 Hold Poker APRI Who: People with Passion and Purpose What: Dedicated to Transforming Healthcare for Patients, Providers, and Payors How: Patient-Centric, Physician-Led, and Population Health Management Focused 3: De gh#2Foresight Acquisition Corp. Is Led By A World Class Management Team With Deep Operational And Investing Expertise Greg Wasson Chairman of the Board Walgreens WE Mark Thierer Advisor Health WASSON ENTERPRISE Dentsply Sirona Currently serves as President and Founder of his family office, Wasson Enterprise Former CEO and President of Walgreens from 2009 to 2014. Served Walgreens for 34 years, creating significant financial and shareholder value by initiating transformative mergers and investments, leading organizational change, assembling diverse leadership and establishing the company's position as an industry leader Invested and nurtured a portfolio of investments by adding value through his ability to catalyze relationships for businesses, channel partners, key hires, and strategic investors to build sustainable, high-growth businesses that do well by doing good ■ Recognized throughout the drugstore and healthcare industry for transformational leadership, innovation, bold business decisions, and executing on strategic long-term visions Lifelong leader in the healthcare space and known for his ability to transform companies and achieve financial and operational success Transformed a small pharmacy benefit management company (PBM) called SXC Health Solutions into one of America's biggest and fastest growing players - then facilitated its $12.8 billion sale to Optum ■ Former CEO of OptumRx from 2015 to 2017 Former CEO and Chairman of Catamaran from 2006 to 2015 OPTUM RX 2 Michael Balkin Chief Executive Officer and Director William Blair PHS performance health systems Kermit Crawford Advisor RITE AID SYCAMORE PARTNERS Deep experience in both private and public markets across Long-term focus on sustainable growth and development the entirety of the capital structure with the ability to add value Former Partner and Co-Manager of the William Blair Small Institutional portfolio and Small Cap Growth Fund Over 30 years of experience working with public companies in the small cap space Currently the Chairman of the Board of Performance Health Systems Former Partner at Magnetar Capital, LLC, a multi-strategy hedge fund Co-founded Cityview Associates, a real estate investment firm Bankers Trust. V FIRST CHICAGO The First National Bank of Chicago MAGNETAR CAPITAL A pharmacy, health and wellness expert who has led transformational change and cost-saving programs in highly competitive consumer-focused businesses Previously served as an Operating Partner, Advisor and Consultant for Sycamore Partners, specializing in retail and consumer investments Former President and COO of Rite Aid Pharmacy tu C.H. ROBINSON TransUnion. Aligned interest across SPAC, Wasson Enterprise and investors P3#3P3 Health Partners: Nationally Scalable, Capital Efficient, Physician-Led Partnership Model Population Health Deeply Experienced Team Improved Speed to Scale Rapidly Scalable Model Addresses A Major Issue Partner vs Build Model Capital Efficient Growth Payor + Provider Market Entry Strategy Drives Organic Growth Proven Medical Cost Mgmt Strong Value Prop Attractive Economics Led by one of the most experienced management teams in population health Leverage experience and learnings from Health Care Partners to improve speed and scale to market Core care management model based on 20+ year experience in medical cost management Physician-led organization helps drive local market PCP affiliate partnerships Low barriers to adoption: Strong demand from health insurers to capitate risk for Medicare Advantage lives ➤ Leverages existing installed physician base across U.S. enabling accelerated market entry Addresses scaleability issue of previous models that attempted to scale, but failed Partner with existing physician base (affiliate model) versus building new (employed / clinic model) Built-in patient panel day 1 vs lag in building Capital efficient market entry - not acquiring doctor groups and no deep and lengthy J curve to maturity Expected near-term path to profitability Rapid full provider network build in local markets to enhance speed of scale Enters market with payor partnerships to accelerate member growth, attribution and fully delegated risk Partners with local providers vs displacing, maintaining the patient and physician relationship Develops full network of primary care, specialty and ancillary providers Target Medicare Advantage ("MA"): Unique and significant opportunity to drive waste out of the system Strong economic potential under value-based care ("VBC") arrangements Proven care management model delivers high-quality, low cost care to Medicare Advantage members Significant investment in tech enabling care model to drive better patient outcomes and economics ¹ Represents 2021E projections; 2 Represents long-term target Please see slides 50-52 for important information and legal disclaimers regarding certain matters, including: (i) confidentiality; (ii) forward-looking statements; (iii) use of projections; and (iv) financial measures 20+ Year Track Record HealthCare Partners Experience $0 To $600mm¹+ Revenue In 4 Years High ROI Model Limited Capital Investment & Cash Burn vs Other Models 11 Markets, 4 States In 4 Years Expected 3-5 New Markets Annually 35% LT Patient Growth² Track Record Of Meaningful MCR Improvement 20%+ LT EBITDA Margin² P3#4Today's Presenters W Sherif Abdou, MD, MMM, FACP, FACPE Chief Executive Officer P3 People. Passion. Purpose. Health Partners Amir Bacchus, MD, MBA Chief Medical Officer FORESIGHT Empowering Innovation Through Operating and Investing Expertise Eric Atkins, CPA, MBA Chief Financial Officer Greg Wasson Michael Balkin Chairman of the Board Chief Executive Officer and Director Note: Presenters may include a subset of members presented on this page from both P3 Health Partners and Foresight Acquisition Corp. Mark Thierer Advisor Who: People with Passion and Purpose What: Dedicated to Transforming Healthcare for Patients, Providers, and Payors How: Patient-Centric, Physician-Led, and Population Health Management Focused P3#5P3 At A Glance We Operate In A Rapidly Growing ~$300bn Medicare Advantage Market By Partnering With Payors And Physicians To Enable Value-based Care We Are A Market Leader With A Strong Track Record Of High Growth We Are... A physician founded and led organization that works collaboratively with physicians, care teams and practices on their journey from traditional fee-for-service to value-based care We Leverage... Our deeply-integrated and capital efficient care model, data and technology, physician leadership and community outreach tools We Create... Enhanced patient outcomes and experiences, greater professional satisfaction for providers and caregivers and lower care costs 11 Operates in 11 markets across 4 states -27K Shared savings lives managed under 5 ACO agreements to date -2,000 2021E PCPs in network 16 MA risk plans contracted to date Note: Physician and patient numbers are approximate 1 Represents long-term target 200+ Years of combined experience -68K Full-risk lives managed by 2021E $630mm+ 2021E revenue 20%+¹ Long-term EBITDA margin#6Proven Outcomes, Compelling Economics And Physician-Led Via our patient- centric, physician-led care model, we are able to drive enhanced outcomes: cia Ag 99% Physician retention ¹ P3 Health Partners Medical Group Built by Doctors. Loved by Patients. 97% Patient satisfaction² ~135% Annual revenue growth³ PA-C castan 35% / 36% Reduction in hospital admissions4 / ED visits5 1 Represents affiliate provider retention through Q1 2021A; 2 Represents patient satisfaction for Nevada Medical Group from February 2020 to February 2021; 32018A - 2020A revenue CAGR; 4 Based on P3's hospital admission rate per thousand of 161 in Arizona as of December 31, 2019, compared to the local Medicare benchmark of 248; 5 Based on P3's emergency department claims per thousand of 357 in Arizona as of December 31, 2019, compared to the local Medicare benchmark of 557 P3#7Right Space Right Space P3 Investment Highlights: Right Space, Right Team, Right Model Right Team Right Team Right Model Right Model Large Opportunity To Partner With Physicians & Payors To Accelerate The Move To Value-Based Care Opportunity Of ~$800bn Medicare Spend¹, Growing At ~7% Per Annum¹, And ~60mm Eligibles² Founded And Led By Seasoned Management Team With Deep Value-Based Care Expertise Proven Track Record Deep Experience In Population Health Management Across Multiple Markets Care Model Informs Business Model (A Win For All): Patients, Physicians And Payors Fully Delegated Model³ Ability To Enter Markets: Capital Efficient Provider Networks Proven Flexible Growth Model Allows For Multiple Routes Of Market Entry; Scalable At Larger Level 12019 Medicare national healthcare expenditure, CMS; 22019 Medicare beneficiaries, Kaiser Family Foundation; ³A fully delegated model occurs when all functions related to the payor-provider integration model are delegated to an organization like P3, for example: network management, medical management, IT / data / analytics, funds flow management, quality management, and other services P3#8Right Space Right Team Right Model P3 Has A Substantial Market Opportunity Annual U.S. Healthcare Spend ~$3.8tn¹ Medicare Spend -$800bn² Medicare Eligibles ~60mm³ Core Medicare Advantage Market -$300bn4 Medicare Advantage Members ~24mm5 Total Addressable Market Opportunity • Includes Medicare eligibles who utilize either Traditional Medicare and / or Medicare Advantage • Medicare eligibles represent ~18% of the US population and growing • ~7% Medicare spending growth rate² Core Medicare Advantage Market: -$300bn Moderate-to-highly populated Medicare Advantage eligible dense counties (>10k Medicare eligibles) $1,000 per member per month ("PMPM") ● ● 1 2019 total national healthcare expenditure, CMS; 2 2019 Medicare national healthcare expenditure, CMS; 3 2019 Medicare beneficiaries, Kaiser Family Foundation; 4 Based on CMS Medicare Advantage Penetration by County data as of March 2021 and includes counties with greater than 10,000 Medicare eligibles. Derived by taking the product of ~24mm Medicare Advantage enrollees in our target markets and an annual revenue of $12,000 per member, which is derived from industry knowledge and is what we believe to be a reasonable national assumption; 5 Based on CMS Medicare Advantage Penetration by County data as of March 2021 and includes counties with greater than 10,000 Medicare eligibles; 6 Based on a U.S. population of ~330mm (U.S. Census data) and ~60mm Medicare eligibles P3#9Right Space Right Team Right Model P3's Proven Care Model Addresses Some Of The Largest Challenges In Healthcare Today UNCONTROLLED HIGH COSTS INCONSISTENT OUTCOMES POOR ACCESS P PHYSICIAN BURNOUT Via its integrated tech-platform, P3 empowers physicians, care teams and practices to drive better patient outcomes while maintaining high satisfaction on their journey to value- based care Healthcare Fee-For-Service Transition To Value-Based Care P3#10Right Space Right Team Our Fast Growing PCP Network Has Ample Whitespace... Total U.S. Primary Care Providers <1% penetration 1,500 Right Model P3 2020 Total Contracted PCPs Source: Kaiser Family Foundation; Note: P3 Physician numbers are approximate 1 Represents affiliate provider retention through Q1 2021A 491,060 2020 U.S. Total PCPs PCP Population Across Our Current Mature Markets Arizona -10% penetration 850 8,780 P3 2020 Total 2020 Arizona Total Contracted PCPs PCPs Nevada -10% penetration 300 P3 2020 Total PCPs 3,111 2020 Nevada Total PCPs Oregon ~6% penetration 350 P3 2020 Total PCPs 6,055 2020 Oregon Total PCPS > Proven ability to leverage local market resources to attract providers ➤ "Win-Win" ethos promotes growth and retention in provider network as well as managed lives ➤ Our innovative technology suite drives better patient outcomes and improved provider experience, resulting in a 99% physician retention rate¹ → Flywheel Effect P3#11Right Space Right Team Right Model ...Allowing Us To Grow Into The Rapidly Expanding MA Opportunity That Is Uniquely Addressed By Nextgen Provider Organizations Medicare Advantage % of Total Medicare Enrollment¹ ΜΑ Lives P3 2010 ~11mm Health Partners 24% ~68k MA lives 39% OPRIVIA HEALTH 2020 ~24mm NextGen Providers² OAK STREET HEALTH -83k MA lives ~109k MA lives CanoHealth -85k MA lives 51% 2030 -33mm agilon health -210k MA lives Key Tailwinds Aging U.S. population: 49mm people age 65+ in 2016 → 81mm by 20404 ► 10,000 seniors age into Medicare each day, with -39% choosing MA plans4,1 Medicare Advantage spend expected to grow ~9% annually from ~$300bn to $450bn+ between 2021- 2025, representing 40% of total Medicare spend5 ➤ 67% of Medicare beneficiaries have 2+ chronic conditions6 Individuals with 2+ chronic conditions account for 94% of Medicare spending6 ➤ 99% of Medicare beneficiaries have access to at least one MA plan¹ ~2% of Total MA Enrollment³ 1 Kaiser Family Foundation; 2 P3 MA lives projected as of FYE 2021, Privia MA lives as of FYE 2020, Oak Street MA lives represent midpoint of FYE 2021 management guidance as of 3/31/21, Cano Health MA lives as of Investor & Analyst Day Presentation on 3/04/21, agilon MA lives as of S-1 filed on 3/18/21; 3 Based on 2020 total MA enrollment of ~24mm; 4 U.S. Census Bureau; 5 CMS Medicare Trustees Report (2019) and equity research; 6 July 2020 State of Medicare Advantage Report, Better Medicare Alliance 10 P3#12Right Space Sherif Abdou, MD, MMM, FACP, FACPE Deeply Experienced Executive Team With 20 Years In Population Health Chief Executive Officer • Co-Founder & CEO, Health Care Partners Nevada • Co-Founder & CEO, Pinnacle Health System Right Team 30 Years of Experience Unmesh Srivastava Chief Technology Officer • Head of Innovation and Business Transformation, Optum ● Director of Innovation & Transformation, UnitedHealth Right Model Group 8 Years of Experience Amir Bacchus, MD, MBA Chief Medical Officer • Co-Founder & CMO, HealthCare Partners Nevada • Co-Founder & CMO, Pinnacle Health System 23 Years of Experience ↓ Don Trexler, MBA, MHA Chief Administration Officer • Senior Director, Alvarez & Marsal • Market President, Louisiana, ChenMed 10 Years of Experience Lorie Glisson Chief Operating Officer • President & CEO, HealthCare Partners Florida • President & CEO, JSA Healthcare Corporation 25 Years of Experience Sarah Bussmann, BSN-RN, CRNI, MHA EVP, Population Health Management • Associate VP, Clinical Quality, DaVita Health Care Partners 10 Years of Experience Todd Lefkowitz, MHA Chief Managed Care Officer • SVP, Managed Care Operations & Network Development, HealthCare Partners • VP, Network, PacifiCare & United Healthcare-Nevada 20 Years of Experience Michelle Ross Market President - OR ● • SVP, MRA, DaVita HealthCare Partners • SVP, Clinical Enterprise, HealthCare Partners 20 Years of Experience Dave Yarger Market President - AZ ● CEO, Arizona Connected Care • Network Operations, Partners Health Plan 25 Years of Experience Jessica Puathasnanon, JD, LLM Chief Legal Officer . Chief Counsel & Compliance Officer, Medtronic Diabetes • Director, KPMG SEC Enforcement 11 Years in Healthcare Market President - NV VP, People Services, DaVita HealthCare Partners ● Hartley White ● • VP, People Services & Wisdom, DaVita Health Care Partners 20 Years of Experience • Eric Atkins, CPA, MBA Chief Financial Officer • CFO, Sprout Pharmaceuticals • Divisional CFO, Hillrom Director, KPMG 9 Years in Healthcare 11 P3#13Right Space 1998 First full-risk contract Founding members of P3 take on their first full-risk contract at Pinnacle / Summit Right Team P3: 20 Years In The Making Right Model 2006 Pinnacle / Summit Acquired by JSA (becomes Health Care Partners Nevada) -35K MA global risk lives Pre-P3 Health Source: DaVita Health Care Partners merger presentation, May 2012; Optum press release, May 2007 1 As of 12/31/11 Note: Pre-P3 events based on management's knowledge Scaling the business -100K MA global risk lives 2010 2012 Health Care Partners Merges with DaVita ~125K MA global risk lives ~21.8%¹ EBITDA margin P3's first full year of revenue Revenue of $88mm 2017 P3 People. Passion. Purpose. Health Partners Founded 2018 2019 P3 expands into 6 new markets for a total of 11 P3 achieves 7 full risk payor contracts P3 Health 2020 2021 Projected revenue of $633mm P3 Health Partners People. Passion. Purpose. FORESIGHT#14Right Space Enterprise Value Operating Model Year Founded P3 Health Partners Compares Favorably Across Key Metrics Health Partners Relationship Between PCP And Patient Growth Strategy Markets MA Membership5 2021E Revenue 2022E Revenue FV / 2022 Revenue Capital Efficiency Fully Delegated Model LT EBITDA Margin Target Right Team '18A-'20A Revenue P3 $2.3bn Partner - Payor / provider 20183 Supports and enables the existing PCP / patient relationship De novo, acquisition & MSO 11 -68K $633mm $825mm 2.8x Right Model High Yes 20%+ 135% OAK STREET HEALTH $13.7bn¹ Build - Employed / clinic model 2012 Disrupts existing PCP / patient relationship De novo 20 ~109K $1.3bn¹ $2.0bn¹ 6.7x Low No ~20% 67% CanoHealth agilon health $6.1bn² Buy - Acquisition primarily 2009 Supports and enables the existing PCP / patient relationship De novo, acquisition & MSO 15 ~85K $1.5bn6 $2.2bn6 2.7x Low No N/A8 90% $13.0bn¹ Partner - Joint-venture PCP 19834 Supports and enables the existing PCP / patient relationship De novo, acquisition & MSO 17 ~210K $1.6bn¹ $2.4bn¹ 5.5x Low No Double digits 60% OPRIVIA $3.4bn¹ Partner - Provider 2013 Supports and enables the existing PCP / patient relationship Primarily MSO & VBC 6 states/70 MPSAs ~83K $1.3bn7 N/A N/A High No ~5% (gross revenue) -30%+ (net revenue) 18%7 CAGR 1 FactSet as of 5/24/21; 2 Based on Jaws Acquisition Corp. share price as of 5/24/21 and 473.2mm fully diluted shares outstanding; ³ First full year of revenue; 4 Date of incorporation for Primary Provider Management Company, Inc ("PPMC"), which was the predecessor to agilon Health; 5 P3 MA lives projected as of FYE 2021, Privia MA lives as of FYE 2020, Oak Street MA lives represent midpoint of FYE 2021 management guidance as of 3/31/21, Cano Health MA lives as of Investor & Analyst Day Presentation on 3/04/21, agilon MA lives as of S-1 filed on 3/18/21; 6 Sourced from Investor & Analyst Day Presentation on 3/04/21; 7 Represents 2020A total practice collections; 82023E EBITDA margin of 6% and average mature MA clinic adj. EBITDA margin of 24% 13 P3#15Right Space Right Team Innovative, Patient-Centered And Physician-Led Care Delivery Model Clinical Ownership Right Model Adoption of Best Clinical Practices Data Reporting Health Promotion and Disease Prevention Risk Stratification Lower Cost Of Care Improved Clinical Outcomes Improved Clinical Experience Improved Patient Experience Physician Engagement Population Engagement Access Care Integration and Coordination Understanding Population's Disease Burden 14 P3#16Right Space Right Team Delegation of Services Creates Value Key delegation services... ول ||||' Right Model Network management and credentialling Utilization management Care management Claims processing ...help accelerate the reduction of medical costs Example: ~$99 PMPM P3 ♥aetna -$41 PMPM Aetna's oncology costs, in Nevada, were $99 per member per month (PMPM) Aetna partners with P3 P3 modifies Aetna's network by removing a single oncology firm Estimated run rate savings of ~$58 PMPM (reduction from $99 to $41 PMPM) 15 P3#171 Right Space How We Bend The Cost Curve 2 3 4 Right Team 5 Care Management Right Model Utilization Management Proprietary Tech Platform Collaboration with Payors to Build the Right Network Selectively Deploy Staff Model ● ● ● • Direct care to most cost efficient, high-quality providers Perform concurrent review to manage acute and post-acute hospitals for length of stay and appropriateness Reduce unnecessary services through provider education and guideline usage ● • Drive physician efficiencies via multi-layered technology platform, leading to better overall care Consolidate disparate data to enhance patient-specific care Increase access for patients Prioritize high-risk, high-cost, rising-risk patients Focus cost management efforts via direct patient and provider interaction Contract with key providers / specialists to encourage coordination • Contract with key providers for directing large volumes of ● patients Direct care to strong quality, cost efficient providers ● ● ● Improve access in an area Purchase an existing practice Provide wellness activities to seniors Align PCP Incentives To Deliver Optimal Care 16 P3#18Right Space Right Team Our Technology Suite Enables The Delivery Of High-Quality Care At Scale Inputs - Fragmented ✓ 250+ fragmented, disparate data points per month from payors, vendors and care facilitates ✓ Claims adjudication data ✓ Contracting/credentialing ✓ Payment integrity information Right Model ✓ Other COTS applications Technology Platform - Built For Purpose Multi-Layered Tech Stack Enables Our Effective Care Model And Quadruple Aim: Lower Cost of Care, Improved Clinical Experience, Improved Patient Experience, Improved Clinical Outcomes P3 Care Connect Utilization management P3 Velocity: Multi-faceted reporting tool LO 5 Excelerate Back Office Suite: End-to-end back office integration across the care continuum 6 P3 People, Passion. Purpose. Health Partners 1 3 P3 Care Connect: ■ Care management 2 P3 Care Connect: ■ Disease management Excelerate Provider: ■ Integrated provider dashboard Value - Proven ✓ Data-backed solutions and care provision ✓ Seamless transition of payor and patient data across platforms ✓ Real-time data sharing ✓ Predictive analytics and risk stratification ✓ Standardized workflows across complex patient panels 17 P3#19Right Space How Our Products Interact Together Internal Systems Claims Adjudication Contracting/ Credentialing Right Team Payment Integrity Medical Group ez cap TractManager HCIM athenahealth Other COTS Applications (eg., Netsuite, Namely, Footprints etc.) External Data Sources (Payors, vendors, care facilities) > 250 disparate files per month Right Model Information Security (HITRUST) P3 Data Fabric Staging & Quality Checks Data Integration & Mastering Analytics, Business Rule Curating, Product Schema Cloud Computing Azure (MS Azure) User Provisioning & Access P3 P3 Velocity P3 Care Connect P3 Excelerate N-Gage P3 Health Hub Endpoint Management One Login Provider Facing Analytics Retrospective Coding Management Bl Letter Processing Patient Engagement Remote Monitoring Self Assessment CV Submission For MRA Prospective Coding ML & AI Utilization Management Care/Disease Mgmt. Televisit Delegate Engagement Communication/Connectivity 18 P3#20Right Space Right Team M The P3 Model Is Effective, Differentiated And A "Win" Scenario For All Key Stakeholders Right Model Patients P3 honors the social and moral contract between patients and physicians ➤ All patients aligned to the payor and provider Physicians Partners with local providers vs displacing providers to maintain patient and provider relationships ➤P3 contracts and develops a full network of primary care, specialty and ancillary providers Payors > P3 partners directly with payors Receive inbound requests from payors to improve growth, quality and profitability in their existing markets ➤ Significant and growing demand from payors to capitate risk and transition to VBC The P3 Model Enables Better Patient Care, Greater Physician Satisfaction, And Enhanced Payor Growth And Cost Savings 19 P3#21Right Space Right Team Our Fly Wheel Drives The Repeatability Of Our Care Model And Its Outcomes High Patient And Provider Satisfaction Backed By Proven And Exceptional Better Quality Of Care 6 5 Right Model High quality of care meaningfully reduces the cost of care 35% reduction in hospital admissions4 Value of model creates better care outcomes 36% reduction in ED visits³ 4 Lower care costs Improved care outcomes Multi-layered technology platform, driving integration across the care continuum Aggregates 250+ data points Higher patient satisfaction P3 Improved membership and retention Health Partners People. Passion. Purpose. Enhanced tech platform Higher physician efficiency and satisfaction Greater payor engagement 1 Greater care continuity and improved care promote patient stickiness 97% patient satisfaction¹ 3 2 Robust payor relationship across markets and patient panels 16 MA risk contracts to date High physician satisfaction 99% physician retention² ¹ Represents patient satisfaction for Nevada Medical Group from February 2020 to February 2021; 2 Represents affiliate provider retention through Q1 2021A; ³ Based on P3's emergency department claims per thousand of 357 in Arizona as of December 31, 2019, compared to the local Medicare benchmark of 557; 4 Based on P3's hospital ad on rate per thousand of 161 in Arizona as of December 31, 2019, compared to the local Medicare benchmark of 248 20 P3#22Right Space Right Team Proven Care Outcomes, Enhanced Patient And Provider Satisfaction "C P3 is all about patient care. P3 gets things turned around quickly... Contracting with P3 is a feather in your cap Right Model "" Dr. Peter Caravella (Affiliate Doctor, LV Surgical Associates), Nevada "C I have found that coordination of care is never a cumbersome process as appropriate individuals in the organization are always approachable and easily reachable "" - Dr. Gary Chen (Comprehensive Digestive Institute of Nevada), Nevada 35% reduction in hospital admissions¹ "G We couldn't reach our past doctors on the phone, and when you need a call back you didn't get one. We haven't had that problem with P3 ララ Thomas, P3 Patient "C I wanted to come to the doctors at P3 because they cared about me, they showed me interest. That was a great happiness for me "J - Alfonso, P3 Patient 99% 97% patient satisfaction² physician retention³ ¹ Based on P3's hospital admission rate per thousand of 161 in Arizona as of December 31, 2019, compared to the local Medicare benchmark of 248; 2 Represents patient satisfaction for Nevada Medical Group from February 2020 to February 2021; 3 Represents affiliate provider retention through Q1 2021A 21 P3#23Right Space $ Right Team Capital Efficient Market Entry Enables Capital Efficient Growth GA Right Model We Enter Markets Through Partnerships With Payors And Providers Payors Providers Health plans seek P3 to optimize entire blocks of existing business Establishes contracts based on market data in provider contracting, including payor relationships and payment methodologies • Improved outcomes and realized cost savings allow for repeatable, faster growth in the market • Market analysis based on network, market and senior population dynamics Network team identifies existing physician services that align with the P3 model Strong reputation for improving clinical and financial outcomes with installed provider base • Hire / contract with local resources that have established relationships within the market to identify provider groups that align with the P3 model of care P3#24Right Space Right Team Examples Of Growth: Centene Case Study Membership Growth Across States OR Douglas County CA 2019 NV Clark County AZ Yuma County Right Model Pima County Santa Cruz County 2020 Cochise County 2021 15,000 12,500 10,000 7,500 5,000 2,500 0 ■ Pima (AZ) Proven, Agile Model Allows for Rapid Scale ~1k Jan-19 ■Cochise (AZ) CENTENEⓇ Corporation ~10k CAGR: +233% Yuma (AZ) Jan-20 Santa Cruz (AZ) Clark (NV) ~15k Jan-21 Douglas (OR) 23 P3#25Right Space Right Team Examples Of Growth: Arizona Connected Care Case Study Right Model Membership Growth Across Our Most Mature State S Arizona Connected Care your connection for better health Yavapai County 5 Yuma County 4 AZ Pima County 1 Cochise County 2 3 Santa Cruz County ☆ 0 Proven, Agile Model Allows for Rapid Scale Entered into provider partnership with Arizona Connected Care in 2018 that provided core market infrastructure and allowed us to expand our scalable model within the state Our Arizona PCP network grew from ~300 to ~700 between 2018-2019 Expanded network enabled additional risk contracts (1 contract to 4) and accelerated membership growth (~10K full risk lives to ~16K) Shared savings lives obtained with Arizona Connected Care provided springboard for conversion to MA risk and direct contracting 24 P3#26Right Space Right Team Right Model We Have A Strong History Of High Growth And A Line-of-Sight To Continued Success Via Our Flexible, Repeatable Model (FYE 12/31) Total revenue ($mm) Total full risk lives (000s) Total contracted PCPs States (added during year)¹ Markets 2018A $88 10 300 1 Note: Physician and patient numbers are approximate 1 Based on existing sales pipeline 2019A $145 20 1,000 LO 5 2020A $483 50 1,500 11 2021E $633 68 2,000 2022E $825 86 2,500 17-21 '18A-'22E CAGR 75% 71% 70% P3 continues to successfully leverage longstanding relationships with high quality physicians Network development and contracting meaningfully began in Q1'18 Currently operate in 11 markets across 4 states Expected growth to 17-21 markets across 8 states 25 P3#27Right Space Right Team Right Model Strong Markets, Relationships And Growth Trajectory Current states States in pipeline Current counties Select National and Local Payor Relationships Humana aetna CMS CENTERS FOR MEDICARE & MEDICAID SERVICES ☆ Ⓒ BlueCross BlueShield of Arizona CENTENE Ⓡ Corporation Arizona Connected Care your connection for better health Ⓡ WellCare® Health Plans ATRIO™ HEALTH PLANS UnitedHealthcare® 26 P3#28Right Space Right Team Right Model The Foundation Of Everything We Do Is Based On A Scalable And Systematic Approach Repeatable P3 Health Partners People. Passion. Purpose. tiv 2 Care Model Growth Model Partnership Model 27 P3#29Right Space Clear And Visible Path For Growth 8-10% Opportunity Target Long-Term 35% Annual Patient Growth Rate Through a Mix of Payor and Provider Opportunities → Multiple Levers of Growth Existing Contracts Right Team Annual enrollment period ■ Open enrollment period Rest of year Right Model 3-5% Opportunity Existing Counties New payor contracts New provider contracts ¹Estimates are based on management's review of opportunities 3-5% Opportunity New Counties Existing contracts ■ New contracts 3-5% Opportunity New States New payor contracts New network partnerships (JV) Existing contracts 3-5% Opportunity De novo clinics 1-3 clinics per state 3-5% Opportunity Small Clinic Tuck-Ins Targets per market P3's Growth strategy is based on strong existing market growth and a near-term new market entry plan¹ 5-10% Opportunity Large Provider Partnerships ■ Robust near and long-term pipeline P3#30Right Space Right Team Right Model Direct Contracting Represents An Upside To Our Model Current Status • Global risk contracting is only available to 39%¹ of beneficiaries through Medicare Advantage programs 61%¹ of all Medicare beneficiaries are enrolled in Traditional Medicare (fee-for-service) Guidelines and regulations have yet to be finalized; we continue to actively study the opportunity 1 Represents FY2020, Kaiser Family Foundation; 2 Represents 2021E P3 Opportunity -2,000 PCPs² in Network 2023 2027 CMS expanding Global-Risk contracting through DCEs to Traditional Medicare beneficiaries (Projected $488B total addressable market opportunity) Opportunity to aggregate physicians and implement the P3 model Traditional Medicare, 61% Annual Medicare spending ~$800bn per year DCE provides an opportunity to triple the P3 addressable market Medicare Advantage, 39% $800bn 29 P3#31Right Space Track Record Of Growth 10,000 2018A Right Team 20,000 Note: Patient numbers are approximate Total Full Risk Lives 2019A CAGR: 71% 50,000 Right Model 2020A 68,000 2021E 86,000 2022E $88 2018A Total Revenue ($mm) $145 2019A CAGR: 75% $483 2020A $633 2021E $825 2022E 30 P3#32Right Space Revenue ($000s) Select Provider Cohort Analysis Medical expense ($000) Patients Cont. margin ($000s) % cont. margin Right Team MCR (%) $90 ($142) 2018 27 ($52) (58.0%) Right Model 158.0% Provider Cohort A $3,823 ($3,430) 2019 538 $394 10.3% 89.7% $5,757 ($3,963) 1H'2020 1,416 $1,794 31.2% 68.8% ➤ Proven care model with aligned physician incentives drives improved outcomes and reduced medical costs ➤ Represents a selection of engaged physicians across multiple markets Improved medical cost management drove a contribution margin increase from (58%) in 2018 to 31% in 1H20 31 P3#33Right Space Right Team Right Model P3's Projected Mature Market Ramp Commentary • P3's historical and projected growth can be illustrated via a simple cohort analysis • Assuming 10,000 members in year 1, a 35% CAGR implies -33k members by year 5 Revenues expected to correspondingly scale with members, increasing from $84mm in year 1 to $300mm+ by year 5 • In terms of MCR and EBITDA margins, assumes initial, temporary loss, which is expected to quickly shift to break-even and then expected to grow profitability after the first few years • Reflects benefits of driving towards ~70% MLR target over the longer term • Projected margins for year 5+ members are illustratively 28% from year 5 onwards Members (000s) Revenue ($mm) Total MCR EBITDA Margin 10 Year 1 $84 Year 1 93% Year 1 (3%) Projected Cohort Growth CAGR: 35% Year 1 14 Year 2 $104 Year 2 97% Year 2 ■Margin for year 5+ members (7%) 18 Year 2 Year 3 CAGR: 38% $156 -13% reduction Year 3 87% Year 3 3% Year 3 25 Year 4 $218 Year 4 83% Year 4 7% Year 4 co 33 Year 5 $303 Year 5 80% Year 5 10% 28% Year 5 32 P3#34Right Space $mm At-Risk Membership Capitated Revenue Actual And Estimated Income Statement Other Revenue Total Revenue % Growth Medical Cost 1 Other Care Model Expense Gross Profit MCR % Cap. Revenue MCR % Total Revenue Total Operating Expense Opex % of Total Revenue Right Team EBITDA Right Model % Margin Note: Patient numbers are approximate 1 Includes company's estimates for incurred but not reported (IBNR) claims 2018A 10,400 $86 1 $88 (92) (0) ($5) 106.9% 105.4% ($31) 35.1% ($36) (40.6%) Actual 2019A 19,700 $139 $145 65.6% (140) (1) $4 101.5% 96.5% ($37) 25.2% ($32) (22.3%) 2020A 50,600 $476 7 $483 232.7% (477) (5) $2 100.9% 98.7% ($53) 11.0% ($51) (10.6%) 2021E 67,800 $625 $633 31.1% (566) (22) $45 91.2% 89.4% ($85) 13.4% ($40) (6.3%) 2022E 86,400 $818 8 $825 30.4% (678) (33) $114 83.4% 82.1% ($111) 13.5% $3 0.4% Projections 2023E 126, 100 $1,247 8 $1,255 52.0% (1,007) (53) $195 81.1% 80.2% ($148) 11.8% $47 3.7% 2024E 176, 100 $1,756 $1,765 40.6% (1,390) (77) $298 79.4% 78.8% ($191) 10.8% $107 6.1% 2025E 229,400 $2,349 8 $2,358 33.6% (1,823) (105) $429 77.8% 77.3% ($240) 10.2% $189 8.0% 33 P3#35Right Space Provider / Payor Provider A Near Term Opportunities In Our Pipeline Represent 100k+ Lives Does Not Include Strategic Opportunities With National Payors Provider B Provider C Provider D Right Team Payor A Payor B Payor C Payor D Payor E Other Right Model Total 1 Based on information provided by target and management projections Note: Anticipated lives are approximate Anticipated Lives¹ 10,000 10,000 10,000 10,000 8,000 6,000 5,800 5,000 5,000 40,000 100k+ Region Southwest West West Midwest Southwest Southwest Northwest Southwest Northwest Various 5+ 34 P3#36Right Space Right Team Long-Term KPI Targets 3-5 Counties per year 35% Annual membership growth 70% MCR 20%+ EBITDA margin • Leverage existing payor / provider relationships to extend into adjacent markets Established new payor / provider relationships to enter new markets ● ● ● Right Model ● Strategically build / acquire centers in key markets to complement our MSO and affiliate model Improved care outcomes promote strong patient retention and acquisition Reduce MCR across markets, driving better care and carving out unnecessary waste Continuously leverage growing tech platform to drive down medical costs Leverage across administrative and shared services drive improved operating expense margin 35 P3#37Right Space Right Team Right Model P3 Health: Right Space, Right Team, Right Model 8 Right Space ➤ Lack of coordinated care driving unsustainable, high-costs Large, growing Medicare Advantage TAM that is ripe for penetration Strong industry tailwinds Right Team 200+ years of combined healthcare experience > Proven ability to build and scale value-based care platforms -$630mm+ in revenue in ~4 years <] 1000 ん Right Model Care model informs business model > Fully delegated ➤ Capital efficient compared to industry standards Multiple routes of market entry; scalable at a larger level 36 P3#38#VEGAS STRONG P3 People Passion Purse Health Partners EGAS ON- EGAS RONG Hoolth Partners 3 Passion Pup VEGAS RONG 3% Hoolth Partners Het #VEGAS STRONG P3 #VEG STRON P3 VEGAS STRONG 3 Health Health VEGAS TRONG 3 #VEGA TRO #VEGAS STRONG P3 Health Pasalon Purpos #VI STR #VEGAS TRONG VEGAS STRONG Health 3 ste Passion Pures VEGAS RONS Transaction Overview VEGAS 3 VEGA RON Hoolth EGAS VEGAS STRONG 3 Health Portners VEGAS#39Proposed Transaction Overview ● ● P3 Health Partners is preparing to go public through a SPAC Merger with Foresight Acquisition Corp., which is expected to raise at least $200mm PIPE to further support long-term growth FOREU's IPO raised $316mm in February 2021, with its common stock trading on the NASDAQ under symbol "FOREU" The transaction is expected to be funded through a combination of: FOREU's $316mm of cash in trust¹ ● At least $200mm of committed PIPE financing 1 Assumes no redemptions 38 P3#40Pro Forma Capitalization and Ownership Estimated Transaction Sources And Uses¹ ($mm) Sources ($mm) Existing P3 equity rollover SPAC cash in trust Private placement of common equity Total sources Uses ($mm) Existing P3 equity rollover Cash proceeds to selling shareholders Cash to balance sheet from transaction Est. transaction fees and expenses Total uses $1,811 316³ 209 $2,336 $1,811 315 180 30 4 $2,336 1 Transaction expenses are an estimate; 2 Total pro forma shares outstanding assumes 181.1mm from existing P3 shareholders, 31.6mm from Foresight shareholders, 20.9mm from new PIPE investors and 8.7mm from Foresight sponsor. Excludes outstanding public warrants and warrants held by SPAC sponsor and any shares that may be issued in connection with a warrant exchange offer or solicitation of approval to amend the warrants; 3 Assumes no redemptions; 4 May be reduced to the extent SPAC cash in trust is reduced prior to closing by public stockholder redemptions; 5 As of 04/30/21; 6 Includes $180mm of cash to balance sheet from transaction and $14mm from cash on balance sheet of P3 as of 04/30/21 Note: Any lock-up of Company equity holder shares shall be mutually determined by the Company and Foresight in advance of signing of Definitive Agreements (it being understood that such lock-up may be limited to shares issued to executive officers, directors and parties that currently own five percent or more of the outstanding equity interests of the Company) and shall not exceed 180 days; Cash and debt are shown as of 04/30/21 and may fluctuate prior to, and may be more or less at Closing Post-money Valuation At Close ($mm)² PF transaction Illustrative P3 share price PF shares outstanding Total PF equity value (+) debt at close (-) cash at close Total PF enterprise value 2022E revenue 2023E revenue PF 2022E EV / revenue PF 2023E EV / revenue Illustrative Post Transaction Ownership² PIPE shareholders 8.6% Foresight shareholders 13.0% Foresight sponsor 3.6% O Existing P3 shareholders 74.7% $10.00 242.3 $2,423 61 5 (194) $2,290 $825 $1,255 6 2.8x 1.8x 319 P3#41Summary Risk Factors Key Risks Relating to P3 Health Group Holdings, LLC ("P3 Health") and Foresight Acquisition Corp. ("Foresight") Certain factors may have a material adverse effect on our business, financial condition, and results of operations. The summary risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. The list below has been prepared solely for purposes of the proposed private placement offering in connection with the proposed business combination (the "Business Combination") between P3 Health and Foresight Acquisition Corp., a special purpose acquisition company (SPAC), and solely for potential private placement investors in such offering, and not for any other purpose. Accordingly, the list below is qualified in its entirety by disclosures contained in documents filed or furnished in the future by Foresight with the U.S. Securities and Exchange Commission, including the documents to be filed or furnished in connection with the Business Combination. The risks presented in such filings may differ significantly from and be more extensive than those presented below. We have a history of net losses. We expect to continue to incur losses for the foreseeable future and we may never achieve or maintain profitability. Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter. Following the consummation of the Business Combination and private placement offering, we will need to raise additional capital to fund our existing operations, develop and commercialize new services and expand our operations. The COVID-19 pandemic has impacted, and may continue to impact, our operations and may materially and adversely affect our business and financial results. We rely on our management team and key employees and our business, financial condition, cash flows and results of operations could be harmed if we are unable to retain qualified personnel. Our growth depends in part on our ability to identify and develop successful new geographies, physician partners, payors and patients. If we are not able to successfully execute upon our growth strategies, there may be a material adverse effect on our business, financial condition, cash flows and results of operations. ● ● ● . ● ● . ● ● If growth in the number of patients and physician partners on our platform decreases, or the number of products or services that we are able to provide to physician partners and patients decreases, due to legal, economic or business developments, our business, financial condition and results of operations will be harmed. Under most of our agreements with health plans, we assume some or all of the risk that the cost of providing services will exceed our compensation. A failure to accurately estimate either payments owed to us or incurred but not reported medical expense could adversely affect our results of operations and result in reduced revenues and/or increased expenses and therefore losses that are significantly higher than initially reported or reductions in income. If the estimates and assumptions we use to project the size, revenue or medical expense amounts are inaccurate, our future growth prospects may be impacted and we may generate additional losses or fail to attain financial performance targets. We primarily depend on reimbursements by third-party payors, as well as payments by individuals, which could lead to delays and uncertainties in the timing and process of reimbursement, including any changes or reductions in Medicare reimbursement rates or rules. One of P3 Health's existing equity holders has asserted it has a contractual option to purchase additional equity interests in P3 Health in connection with the proposed transactions with Foresight. If applicable, it would result in a $25 million capital inflow to the P3 Health and shift the relative equity ownership of the existing P3 Health owners. P3 Health does not agree that such contractual option applies to this transaction as structured, and that specified exceptions apply. P3 Health and Foresight have proposed a transaction structure such that any exercise of the option, if it applied, would not result in dilution to existing investors in Foresight or investors in the private placement. However, no assurance can be made that this issue will not ultimately result in litigation by and among the existing equity holders of P3 Health. Changes in the payor mix of patients and potential decreases in our reimbursement rates as a result of consolidation among health plans could adversely affect our revenues and results of operations. The impact on us of recent healthcare legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may adversely affect our business, financial condition and results of operations. 40 103#42Summary Risk Factors (Cont'd) The healthcare industry is intensely regulated at the federal, state and local levels, including regulations regarding our agreements or arrangements with any physician equity holder of our practices, and government authorities may determine that we fail to comply with applicable laws or regulations and take actions against us. In addition, laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business, and the failure to comply with such laws could subject us to penalties or require a restructuring of our business. ● ● ● ● ● ● ● ● The termination or non-renewal of the Medicare Advantage contracts between Centers for Medicare and Medicaid Services (CMS) and the health plans with which we contract, or the termination or nonrenewal of our contracts with those plans, could have a material adverse effect on our revenue and our operations. We are dependent on physician partners and other providers to effectively manage the quality and cost of care and perform obligations under payor contracts. Reductions in the quality ratings of the health plans we serve could have a material adverse effect on our business, results of operations, financial condition and cash flows. We have relationships with affiliated independent physicians and group practices that we do not control to provide healthcare services, and our business could be harmed if a material number of those relationships were disrupted or if our arrangements with such providers become subject to legal challenges, liabilities or reputational harm. Our business is concentrated in certain geographic regions, which makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions. We depend on our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. If we are unable to obtain and maintain sufficient intellectual property protection for our technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and services similar or identical to ours, and our ability to successfully commercialize our technology and services may be impaired. If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed. While we have taken steps to protect our intellectual property, we may be involved in litigation claiming that we have infringed on a third party's intellectual property or in litigation enforcing our intellectual property, which could be time consuming and costly and may adversely affect our business, financial condition, results of operations and prospects. 41 P3#43Summary Risk Factors (Cont'd) Risks Related to the Business Combination and the Private Placement Except as otherwise noted below, references to "we" and "our" below refer to Foresight Directors of Foresight have potential conflicts of interest in recommending that our stockholders vote in favor of approval of the Business Combination. Foresight's initial stockholders, officers and directors have agreed to vote in favor of the Business Combination, regardless of how our public stockholders vote. Foresight's sponsors, directors, officers, advisors, and their affiliates may enter into certain transactions, including purchasing shares or warrants from public stockholders, which may influence a vote on the Business Combination and reduce the public "float" of our securities. ● ● ● Subsequent to the consummation of the Business Combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which could cause you to lose some or all of your investment. We may invest or spend the proceeds of the Business Combination and private placement in ways with which the investors may not agree or in ways which may not yield a return. Each of Foresight and P3 Health have incurred and will incur substantial costs in connection with the Business Combination, private placement and related transactions, such as legal, accounting, consulting, and financial advisory fees, which will be paid out of the proceeds of the Business Combination and the private placement. There can be no assurance that the common stock issued in connection with the Business Combination will be approved for listing on Nasdaq following the closing, or that we will be able to comply with the continued listing standards of Nasdaq. The ability of Foresight's public stockholders to exercise redemption rights with respect to a large number of shares could deplete Foresight's trust account prior to the Business Combination and thereby diminish the amount of working capital of the combined company. Uncertainty about the effect of the Business Combination may affect our ability and the ability of P3 Health to retain key employees and integrate management structures and may materially impact the management, strategy, and results of our operation as a combined company. 42 P3#44Appendix#45P3 Excelerate - Provider Interface ● Helps improve provider performance, quality and alignment to payment incentives Seeks to drive revenue through coding and chart review Provider of ADT alerting HEDIS/STAR Improvement HCC Recapture Drug Opportunities RAF Management P3 Excelerate Iveson, Kathleen PRACTICE: ABC HEALTHCARE 235 ACTIVE MEMBERS HIGH RISK-3 SORT: Risk 172 N NEW MEMBERS RISING RISK-25 138 NO PCP VISIT OTHER RISK-207 T FILTER HJonathon Doe last visit: 3/13/2019) Recent Admit Acute STAR Cpps 2 Drug Sub Opps 01 Suspect Dic 1 Historical Cxc3 HRichard Jones (last visit: na STAR Opps 3.1. Drug Sub Opps 01 Suspect Dic41 Historical Dx 3 Physicians Dashboard H Mark Walton (last visit n/a) Recent Admit ER LTAC STAR Opps: 91 Drug Sup Oppe 0. Suspect Dx 4. Historical Dic 3 R Jamie Nicolson (last visit: n/a) STAR Opps 2 | Drug Sua Opps 01 Suspect Dc3 | Hstancal Che 3 R Tammy Jamison last visit: n/al STAR Opps 9. 1. Drug Sua Opps 01 Suspect Dx 4 | Historical Dx:3 C Member Explorer > > > OP3 Excelerate Dashboard Member Explorer Physician Dashboard TMC MED NETWORK MEMBERS & METRICS QUALITY OPPORTUNITIES 2715 Member Census (Currently Admitted) 27 ACUTE O As of 08/14/2020 6:40 15 AM Eligibility/Pre-Auth Active Membership (12125) O 12125 0 OBS O Update [05/20/2020) HEDIS 2020 data is now available for Aetna (NV). Allwell (AZ), Anthem (NV), Atrio (OR), Blue Cross Blue Shield (AZ), Hometown Health (NV), Humana (AZ). Select Health (NV), and United (AZ). Please note that this data is as of 03/31/2020 for only Atrio (CR) and BCBS (AZ). All other health plans data is as of 04/30/2020. Senior Commercial MSSP (Senior) Claims 5446 NEW MEMBERS O Resources 2 ER O 60.5% PCP VISIT COMPLETION O 1568 Members Due 497 DRUG SUBSTITUTION OPPORTUNITIES O 0 Switch Dashboard: 0 8 SNF 0 1.36 51% HCC RECAPTURE O Chris Pempsell - Role: UI/UX Designer Last Login: 9/30/2020 5:09 PM 0.772 TMC MED NETWORK Care Mgmt Phone: (520) 392-8975 | Help ACCRUED RAFO Export Summary Report 5-STAR SCORE O 0 REHABO 0% CV COMPLETION O 3970 Members Due 1.5 44 F3#46P3 Excelerate - Back Office Suite P3 Excelerate Coder Member Search Last Name smith Search Results Member Name SMITHIL DONALD SMITHELMER G SMITHIL WILLIAM G SMITH JR, COLIN SMITH JR GREEN SMITH JR JAMES D SMITH JR JAMES W SMITH JR LUTHERT SMITH JR RUDY SMITH JR WILLIAM J Showing 1 to 10 of 283 entries Date of Birth 08-18-1975 12-03-1949 01-07-1940 12-21-1953 07-25-1945 05-26-1935 01-27-1941 12-03-1946 02-11-1967 08-01-1953 First Name Member 10 90T657 678834101 760646001 TEPON34X78 AGI95004471 Current PCP UNASSIGNED FOR HAMANT, MICHAEL MD MUTTERFERL ROBERT DO UNASSIGNED FOR LANE BRIAN PA-D SEARCH Chart Review ID: 23061 Add Codes Date of Birth Health Plan DELETE REVIEW MSSF MESKIHHS ORTEGA BERMUDEZ, ANGEL Astra Showing 0 to 0 of 0 entries Added by Cader United P3 Excelerate Coder United Member Name SMITH II, DONALD Member 10:90T6XM9UF57 Date of Birth: 8/18/1975 AWV Processing MSSF Anthem Medical Conditions DX/CPT Codet DX/CPT II Description Earliest Effective Date 07-01-2018 01-01-2019 07-01-201 03-01-2000 01-01-2000 # Marked for deletion from m Chris Pempsell. Role: UX Desire Last Login 9/30/2020500PM Member Id Show marked for deletion Recent Term Date ADVE Adve Acti Search: Activa Reviewed, no new HCC codes added Show manually added codes Coding Review Status Rendering Provider (Group) Dan D NEEDS REVIEW NEEDS REVIEW Home Phone Not Available POP UNASSIGNED PCP PCP Group: TMC MED NETWORK Chart Review Date: 10/7/2020 HEDIS/STAR Medical Facility Draft Report NEEDS REVIEW NEEDS REVIEW No data available in table NPI Appropriate signature and credent Yes No EMRA no please provide comment Qualified Comprehensive Visit NO EMR FOR ANY PROVIDER FO Provider Type Source ✔Date of Service Review Complete P3 Excelerate Dashboard Provider Communication Physician Dashboard TMC MED NETWORK MEMBERS METRICS As of 08/14/2020 0:49:15 AM Member Explorer → Eligibility/Pre-Auth Member Census (Currently Admitted) 27 ACUTE O QUALITY OPPORTUNITIES 2715 Active Membership (12125) O CARDIOLOGY OPHTHALMOLOGY ERMATOLOGY CT/MRI Update [05/20/2020]: HEDIS 2020 data is now available for Aetna (NV), Allwell (AZ), Anthem (NV), Atrio (OR), Blue Cross Blue Shield (AZ), Hometown Health (NV), Humana (AZ), Select Health (NV), and United (AZ). Please note that this data is as of 03/31/2020 for only Atrio (OR) and BCBS (AZ). All other health plans' data is as of 04/30/2020 12125 Top 5 Specialty Referrals (per K) - Claim Based Specialty PT/OT Updated on 08/14/2020 (DOS Range 01/01/2020 to 08/31/2020) 0 OBS O 5446 NEW MEMBERS O Senior Commercial MSSP (Senior) Group 476 219 211 202 185 Market 413 379 273 141 Claims 236 Coding Reviews E Resources 2 ER Ⓡ 20 10 60.5% PCP VISIT COMPLETION > 1568 Members Due 497 DRUG SUBSTITUTION OPPORTUNITIES Ⓡ Admits As of 08/14/2020 1:42:27 PM 0 Excelerate v2.1.1 Switch Dashboard: ER 8 SNF O YTD In-Patient Utilization (per K) - Census Based 90 80 70 60 50 40 30 1.36 51% HCC RECAPTURE Ⓡ 0.772 Group OBS Chris Pempsell. Role: UI/UX Designer Last Login: 0/30/2020 5:00 PM TMC MED NETWORK Care Mgmt Phone: (520) 392-9975 | Help ACCRUED RAF Ⓡ 5-STAR SCORE Ⓡ Market Export Summary Report SNF O REHAB 0% CV COMPLETION O 3970 Members Due Care Gaps Closure Rehab 1.5 5 e Clinical Member ID Clinical First Name 2019 2020 Current PCP Status Y Health Plan T Reviewed with no findings Home Phone: (520) 889-0683) POP: WILSON, SCOTT MD PCP Group: EL RIO POSSIBLE CONDITIONS Chart Review Created Date: 01/02/2020 TAdded Note SEARCH Code Possible Condition Other psychoactive 05/19/2020 F1010 substance abuse uncompl 01/13/2020 R1110 Vomiting unspecified HYPERFUNCTION OF 501/02/2020 E22 PITUITARY GLAND REVIEWER NOTES Status Added Code Condition Date of Birth Earliest Effective Date DOCUMENTATION IMPROVEMENT OPPORTUNITIES Supporting Evidence Documentation Improvement 33533 esssss gergasd a feg se sadgendg asdgdsages ogsa geodgasdy asafgesogesd asdgsdgs Recent Term Date Added By Action Needed No Documentation Opportunities added ⠀⠀ Jenny Wong Jenny Wong 05/01/2020 01/02/2020 3 Date of Evidence Comments Date of Service Comment Review Created Date Chris Pempsell. Role: UX Designer Lan Legi 9/30/2020 5:09 PM Productivity Snapshot Member Status Report Or Added Date des ad asdasdfasdferdes defe satasarasat sa asas das fasdfsdf and fasdfasdfasdf asdfasd asara asaadstaat asar estes feesd asdfasd asfasdf asd ccccccccc 01/13/2020 01/13/2020 Chart Review Status: Pending Approval Chris Pempsell. Role: UI/UX Designer Last Login: 9/30/2020 5:09 PM Member Id Created By: Jenny Wong Updated By: Jenny Wong Updated Date: 05/19/2020 Created By T APPROVE ALL ✓ 2 Search ADD NEW B Provider B APPROVE ALL 9 ADD NEW B B ALL PENDING APPROVALS Clinical Review Status Y Pending Approval Pending Approval Pending Approval Pending Approval ious 1 Next Network Management 45 $3#47P3 Velocity Business Intelligence Quality Utilization Risk Pharmacy Finance ♡ ] ப 8P3 Velocity Quality - Risk Strategy Rising Risk High Risk N/A OK Number of HCC 20K ESRD OK L 0 Utilization - Provider Group EL RIO TMC MED NETWORK GENERIC-OON P3 MARANA MARIPOSA CENTENNIAL MEDICAL G... UCHC SALEM CLINIC, PC SALEM HEALTH WIKLER FAMILY PRACTIC..... OK: Risk - Pharmacy - 50K 1K 10 Finance- PCP Vaut Status 2K CV No Visit- O Membership 3K 20 4K P&L Patriots- PCP Visit 25 SK Other Market AZ Bing Archive - NVOR Metric San kittle WASHINGTON. EGON NEVADA CALIFORNIA San Dieg Me IDAHO UTAH MONTANA SONORA Chris Pempsell- Role: UI/UX Designer Last Login: 10/7/20207:42 PM WYOMING COLORADO O MEXICO 20 Ciudad Juárez Hermosillo ©2020 TomTom © 2020 HERE. 2020 Microsoft Corporation Terms NOR SOU U Filters Search Filters on this page Enrollment Status is Existing or New Year is 2020 Filters on all pages Year Is (All) Market is (All) County is (All) Health Plan is (All) Line of Business Is (All) Plan Name is (All Group Size is (All) Provider Group is (All) Provider is (All) 2 > vo VQ Al & ML Risk Stratification Admit Prediction Suspect Generation Disease Progression BH 46 P3#48P3 Care Connect - Utilization Management Seeks to Improve Efficiency And Auditability Of Existing Business Workflows Fax Authorization Request Submission Electronic Authorization Request Submission Auth Requests P3 CareConnect Incoming Auths Authorization Queue [ U 0000000000000 Member Name TONGCO, SERAFIN SMITH, LINDA N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Clinical Queue N/A Member ID 0056852400 0055067100 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A Letter Generation Type Y Concurrent Pre-Service Pre-Service Rece Pre-Service 07/08/20 05/ Pre-Service 07/09/2020 6:19:45 Pre-Service Pre-Service 07/09/2020 6:24:59 PM informed by mcg Fax transcription, auto approval and review of medical necessity Pre-Service 07/10/2020 5:05.00 PM 08/11/20206-14:54 PM Pre-Service Pre-Service 08/12/2020 3:51:35 PM Pre-Service 08/12/2020 4:02:07 PM Pre-Service 08/12/2020 406:45 PM Pre-Service 08/12/2020 4:10:45 PM Pre-Service 08/12/2020 7:05:31 PM Member Explorer 08/14/2020 3:10:35 PM Fax Fax Fax Fex Fax Fax Fax Fax N/A N/A N/A N/A N/A N/A N/A N/A Request New Request New Request New Request New Request New Request New Request New Request New Request New Request + CREATE Market Y N/A N/A N/A Oregon Nevada Nevada Nevada Nevada Oregon Nevada Oregon Arizona Arizona Nevada Chris Pempsell Role: UI/UX Designer Last Login: 9/30/2020 5:09 PM UPLOAD UM Reviewer Denielle Meldru N/A Mark Miller N/A N/A N/A N/A N/A N/A N/A N/A N/A Actions: SELECT... N/A Search: N/A Y Process In-Progress In-Progress BEGIN PROCESS BEGIN PROCESS [[[¯¯¯¯¯ BEGIN PROCESS BECIN PROCESS BEGIN PROCESS BEGIN PROCESS BEGIN PROCESS BEGIN PROCESS BEGIN PROCESS BEGIN PROCESS BEGIN PROCESS BECIN PROCESS Provider Notifications E Letter Generation And Fulfillment D Reporting And Audit Compliance 47 P3#49P3 Care Connect - Care Management / Disease Management Program Management Cohort Builder Care Plan Builder Assessment Builder Self-Service Reporting Care Connect Clinical Care Connect Patient Navigation NEW TAB Patient Info te t 13, 1949 ( 71 Years 1 Month) Patient Card TIONS ATIONS Patient Gender Male ? ? ? Ta In All Care Plans Open > Tasks All y Case Number 00012635 Group by Closed > ✓ Diabetes and CKD Care Plan > vx All Care Team Case Number 00012537 All Care ... Status Active Search... Goals Goal Tasks Without Goals Care Plan Status Active vx Goal This is something we want to improve In Timeline Owner Owner ; vx Household v X Last Modified Date Oct 5, 2020, 1:48:23 PM Status Open Last Modified Date Sep 19, 2020, 12:36:27 AM Created Date Oct 5, 2020, 1:48:23 PM Created Date Sep 19, 2020, 12:36:27 AM Powered by salesforce health cloud : +? A New Care Plan New Goal High ? A B C Seeks to Democratize risk management enabling proactive identification and targeting of specific populations Seeks to deliver highly impactful clinical programs aimed at reducing cost and improving patient outcomes Seeks to standardize and optimize care delivery using evidence-based best practices 48 P3#50P3 N-Gage ● ● ● Bi-directional in-app communication between care manager and member using application, facilitated through integration within Care Connect Clinical Message center (email-like capability between member and CM) Two way video Tap to dial (call Care Manager using device phone) Presents member a summary of: Admissions and discharges Biometric data O O O O Care plans Ability to connect remote monitoring device. Data accessible to member and care manager Ability for member to take assessment within application Initial Populations that we are partnering with: Diabetes, CKD and CHF O #fitbit BGL Withings 10136 B .. 97 3 iHealth +) < Health Records TO JAWBONE'. View Trend: GARMIN GlucoDock BIOMETRICS Clinical, Fitness, Wellness and Nutritional Devices, Wearables, Applications and Equipment ●- OMRON P3 N-Gage Weight 152 115 Systolic Temp: 98.6 ressure 07/22/19 DIAGNOSIS MEDICATIONS BMI: 22.9 94 Diastolic Respiration: 15 ET BY YOUR CARE MANAGER 152 Weight Last read: 07/22/19 75 8:31 Height: 5'9" Heart Rate Last read: 07/22/19 to goal 49 P3#51Glossary of Terms ■ Shared savings (lives) - A payment strategy that offers incentives for providers to reduce health care spending for a defined patient population by offering them a percentage of net savings realized as a result of their efforts Full-risk (lives) - A strategy that holds provider organizations fully accountable for the health outcomes of their patients; practices are paid a fee for each patient and then cover all the costs of caring for that patient Value-based care ("VBC") - A healthcare delivery model in which providers, including hospitals and physicians, are paid based on patient health outcomes 50 P3#52Disclaimer CONFIDENTIALITY AND BASIS OF PRESENTATION The information in this presentation is highly confidential. The distribution of this presentation by an authorized recipient to any other person is unauthorized. Any photocopying, disclosure, reproduction or alteration of the contents of this presentation and any forwarding of a copy of this presentation or any portion of this presentation to any person is prohibited. The recipient of this presentation shall keep this presentation and its contents confidential, shall not use this presentation and its contents for any purpose other than as expressly authorized by P3 Health Partners ("P3") and Foresight Acquisition Corp ("Foresight" or "SPAC") and shall be required to return or destroy all copies of this presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this presentation, the recipient is deemed to agree to the foregoing confidentiality requirements. This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination (the "proposed business combination") between P3 and Foresight, and related transactions, and for no other purpose. No representations or warranties, express or implied are given in, or in respect of, this presentation. To the fullest extent permitted by law, in no circumstances will P3, Foresight or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. Industry and market data used in this presentation have been obtained from third party industry publications and sources. None of P3 or Foresight has independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of P3 or the proposed business combination. Recipients of this presentation should each make their own evaluation of P3 and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. FORWARD-LOOKING STATEMENTS Any investment in or purchase of any securities of P3 or Foresight is speculative and involves a high degree of risk and uncertainty. This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expectations and timing related to site build-outs and capacity deployment, potential benefits of the transaction and the potential success of P3's strategy and expectations related to the terms and timing of the proposed business combination and related transactions. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of P3's and Foresight's management and are not predictions of the actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of P3 and Foresight. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, legal and regulatory conditions; the inability of the parties to successfully or timely consummate the proposed business combination, including the risk that the conditions to the proposed business combination are not satisfied or waived, including that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed business combination or that the approval of the stockholders of Foresight is not obtained; failure to realize the anticipated benefits of the proposed business combination; risks related to the effects and uncertainties created by the ongoing COVID-19 pandemic; risks relating to the uncertainty of the projected financial information with respect to P3; risks related to the rollout of P3's business and the timing of expected business milestones; risks related to P3's commercial partnerships, including the inability of P3 and commercial counterparties to enter into definitive agreements; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; P3's ability to manage future growth; P3's ability to develop new products and solutions, bring them to market in a timely manner, and make enhancements to its platform; the effects of competition on P3's future business; the amount of redemption requests made by Foresight's public stockholders; the ability of Foresight or the combined company to issue equity or equity-linked securities in connection with the proposed business combination or in the future; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors discussed in Foresight's Annual Report on Form 10-K for the year ended December 31, 2020 and filed with the SEC on April 6, 2021 (the "Annual Report") under the heading "Risk Factors," and other documents of Foresight filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither Foresight nor P3 presently know or that Foresight and P3 currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Foresight's and P3's expectations, plans or forecasts of future events and views as of the date of this presentation. Foresight and P3 anticipate that subsequent events and developments will cause Foresight's and P3's assessments to change. However, while Foresight and P3 may elect to update these forward-looking statements at some point in the future, Foresight and P3 specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Foresight's and P3's assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. 51 P3#53Disclaimer USE OF PROJECTIONS AND DESCRIPTION OF KEY CONTRACTS AND PARTNERSHIPS This presentation contains projected financial information with respect to P3, namely revenue, gross profit, EBITDA, EBITDA Margin and capital expenditures for 2021-2025. Such projected financial information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such projected financial information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. See "Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the projected financial information contained in this presentation, and the inclusion of such information in this presentation should not be regarded as a representation by any person that the results reflected in such projections will be achieved. Neither the independent auditors of Foresight nor the independent auditors of P3, audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. This presentation contains descriptions of certain key business partnerships of P3. These descriptions are based on the P3 management team's discussions with such counterparties and the latest available information and estimates as of the date of this presentation. In each case, such descriptions are subject to negotiation and execution of definitive agreements with such counterparties which have not been completed as of the date of this presentation and, as a result, such descriptions of key business partnerships of P3, remain subject to change FINANCIAL INFORMATION; NON-GAAP FINANCIAL MEASURES The financial information and data contained in this presentation is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in or may be presented differently in, any proxy statement, registration statement, or prospectus to be filed by Foresight with the SEC. Some of the financial information and data contained in this presentation, such as EBITDA and EBITDA Margin have not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). EBITDA is defined as net earnings (loss) before interest expense, income tax expense (benefit), depreciation and amortization. Foresight and P3 believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to P3's financial condition and results of operations. Foresight and P3 believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing P3's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in P3's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. P3 is not providing a reconciliation of its projected EBITDA, EBITDA Margin and other metrics for full years 2021-2025 to the most directly comparable measure prepared in accordance with GAAP because P3 is unable to provide this reconciliation without unreasonable effort due to the uncertainty and inherent difficulty of predicting the occurrence, the financial impact, and the periods in which the adjustments may be recognized. For the same reasons, P3 is unable to address the probable significance of the unavailable information, which could be material to future results. ADDITIONAL INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND WHERE TO FIND IT The proposed business combination will be submitted to stockholders of Foresight for their consideration. Foresight intends to file a proxy statement (the "Proxy Statement") with the SEC to be distributed to Foresight's stockholders in connection with Foresight's solicitation of proxies for the vote by Foresight's stockholders in connection with the proposed business combination and other matters as described in the Proxy Statement. After the definitive Proxy Statement has been filed, Foresight will mail the definitive Proxy Statement and other relevant documents to its stockholders as of the record date established for voting on the proposed business combination. Foresight's stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement and any amendments thereto and, once available, the definitive Proxy Statement, in connection with Foresight's solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about Foresight, P3 and the proposed business combination. Investors and securities holders may also obtain a copy of the preliminary or definitive Proxy Statement, once available, as well as other documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by Foresight, without charge, at the SEC's website located at www.sec.gov or by directing a request to Gateway Investor Relations, (949) 574-3860, [email protected]. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. 52 P3#54Disclaimer PARTICIPANTS IN THE SOLICITATION Foresight, P3 and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from Foresight's stockholders in connection with the proposed business combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Foresight's stockholders in connection with the proposed business combination will be set forth in the Proxy Statement when it is filed with the SEC. You can find more information about Foresight's directors and executive officers in Foresight's Annual Report. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the Proxy Statement when it becomes available. Stockholders, potential investors and other interested persons should read the Proxy Statement carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. NO OFFER OR SOLICITATION This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. TRADEMARKS This presentation contains trademarks, service marks, trade names and copyrights of P3, Foresight and other companies, which are the property of their respective owners. 53 P3#55000 TITT LLLLL P3 People. Passion. Purpose. Health Partners HB